I agree ralom
even with the sale of infusion I feel more money would be needed
unless a TAVR deal comes in the meantime. I think chances are we will have a cap raise with the new share holders and retails may not get a look in, followed by the sale of infusions ( potentially) to be honest it doesn’t sound hopeful and if we are lucky some sort of deal with TAVR in 2020. i hope I am wrong as I have been so so wrong thus far. obviously all in my no idea opinion
Ann: Response to ASX Appendix 4C Query, page-18
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.50 |
Change
0.070(0.61%) |
Mkt cap ! $243.1M | |||
| Open | High | Low | Value | Volume |
| $11.45 | $11.50 | $11.32 | $90.21K | 7.885K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 53 | $11.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.50 | 2061 | 1 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |